Did you know? You can suggest edits to improve this peptide information.
Overview
What is Survodutide?
Survodutide (BI 456906) is an investigational dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist designed for once-weekly subcutaneous administration. This 29-amino acid peptide with C18 fatty acid acylation represents a novel approach to metabolic disease treatment by simultaneously targeting both energy intake reduction (via GLP-1R) and energy expenditure increase (via GCGR), demonstrating robust efficacy in clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Key Benefits
Dual mechanism for superior weight loss, once-weekly dosing, demonstrated efficacy in obesity/MASH/T2D, well-established safety profile from Phase 2/3 trials
Mechanism of Action
Balanced agonism of glucagon receptors (increases energy expenditure, hepatic fat oxidation) and GLP-1 receptors (reduces appetite, slows gastric emptying) with ~6-day half-life enabling weekly dosing
Pharmacokinetics
Research Indications
Obesity Without Diabetes
Phase 2 trial showed 14.9% mean weight loss at 46 weeks with 4.8mg dose, 55% achieving ≥15% weight loss
Obesity With Type 2 Diabetes
Superior weight loss vs semaglutide (-8.7% vs -5.3%) at 16 weeks in head-to-head trial
Sustained Weight Management
Dual mechanism addresses both energy intake and expenditure, potentially reducing weight regain
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Administer once weekly on the same day. Can be taken any time of day regardless of meals. If you miss a dose and it's within 3 days, take it. If more than 3 days, skip and resume regular schedule.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Remove survodutide vial from refrigerator and allow to reach room temperature (15-30 minutes)
Clean rubber stoppers of both vials with alcohol swabs
Draw prescribed amount of bacteriostatic water into syringe
Insert needle into survodutide vial at 45-degree angle
Slowly inject BAC water down the side of vial to minimize foaming
Gently swirl vial - do not shake vigorously
Allow to sit for 2-3 minutes for complete dissolution
Solution should be clear to slightly opalescent without particles
Store reconstituted solution in refrigerator immediately
Quality Indicators
Clear to slightly opalescent solution
Properly reconstituted survodutide should be clear or have slight opalescence without visible particles
Sealed vial with intact rubber stopper
Ensures sterility and proper storage conditions have been maintained
Within expiration date
Check both powder and bacteriostatic water expiration dates before use
Slight foam after reconstitution
Normal if disappears within minutes - allow to settle before drawing dose
Cloudy solution or visible particles
Do not use - may indicate contamination or degradation
Discoloration of powder or solution
Should be white to off-white powder and colorless solution when reconstituted
What to Expect
- Week 1-4: Possible nausea, reduced appetite - most common during dose escalation
- Week 4-8: Initial weight loss begins, improved satiety between meals
- Week 8-16: Progressive weight loss, potential improvement in energy levels
- Week 16-24: Approaching steady-state levels, more consistent effects
- Week 24+: Sustained weight loss, metabolic improvements become more apparent
- Long-term: Average 15-19% weight loss at higher doses by week 46
Side Effects & Safety
- Common GI side effects: nausea (40-66%), diarrhea (25-49%), vomiting (15-41%)
- Most GI effects occur during dose escalation - use flexible dosing if needed
- Heart rate may increase slightly (mean 2-5 bpm) - monitor if cardiac conditions
- Not recommended in pregnancy or breastfeeding - use contraception
- No dose adjustment needed for hepatic impairment including cirrhosis
- Monitor blood glucose if on diabetes medications - may need adjustment
References
Phase 2 Obesity Trial Without Diabetes (2024)
In 387 participants with BMI ≥27 kg/m² without diabetes, survodutide 4.8mg achieved mean 14.9% weight loss vs 2.8% placebo. 83% achieved ≥5% weight loss, 69% achieved ≥10%, and 55% achieved ≥15% weight loss.
Phase 2 MASH and Fibrosis Trial (2024)
In 293 participants with biopsy-confirmed MASH and fibrosis F1-F3, survodutide improved MASH without worsening fibrosis in 47% (2.4mg), 62% (4.8mg), and 43% (6.0mg) vs 14% placebo. Liver fat reduction ≥30% occurred in 63-67% of treated patients.
Phase 2 Type 2 Diabetes Trial (2023)
Head-to-head comparison showed survodutide achieved greater weight loss than semaglutide 1.0mg after 16 weeks (-8.7% vs -5.3%). HbA1c reductions were dose-dependent, reaching -1.6% with highest doses.
Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia